<DOC>
	<DOCNO>NCT02609646</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetic property critically ill patient use antimicrobial drug ( amikacin , linezolid , meropenem , piperacillin/tazobactam , vancomycin ) . The primary objective identification clinical parameter affect kinetics drug study contribution extracorporeal depuration technique elimination molecule . The secondary objective describe compare therapeutic therapy adopt Intensive Care Units participate project . For molecule , study involve 300 patient admit Intensive Care Units . For patient five blood sample collect average , order measure drug plasma concentration . Patient clinical condition collect electronic clinical record . Finally , basis data , pharmacokinetic model develop describe evolution time drug plasma concentration .</brief_summary>
	<brief_title>AbioKin - Antibiotic Kinetics</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<criteria>patient undergoing antibiotic therapy amikacin , linezolid , meropenem , piperacillin/tazobactam , vancomycin . patient whose antibiotic therapy start stay ICU le 24h admission ICU . patient anticipated length stay ICU least 24h . patient alreadyplaced catheter patient undergo antibiotic prophylaxis lack informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Critically ill patient</keyword>
</DOC>